Utah Medical Products (UTMD) Net Income towards Common Stockholders (2010 - 2026)

Utah Medical Products' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 14.37% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 5.9% decrease from a year earlier, with the FY2025 full-year figure at $10.7 million, down 23.81% from the prior year.
• Net Income towards Common Stockholders climbed to $2.6 million in Q1 2026 per UTMD's latest filing, from $2.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $8.3 million in Q4 2022 and bottomed at -$3.5 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is $3.5 million (2022), against an average of $3.2 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 204.81% in 2022 and slumped 142.72% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $8.3 million in 2022, then tumbled by 142.72% to -$3.5 million in 2023, then surged by 123.26% to $820000.0 in 2024, then jumped by 138.05% to $2.0 million in 2025, then soared by 33.4% to $2.6 million in 2026.
• Per Business Quant, the three latest UTMD Net Income towards Common Stockholders figures stand at $2.6 million (Q1 2026), $2.0 million (Q4 2025), and $2.6 million (Q3 2025).